Navigation Links
YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Date:5/28/2009

MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with head and neck cancer conducted by Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor, at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, Florida from May 29 to June 2, 2009.

The poster entitled "A phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemoradiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancer (abstract # 6041)" will be presented in the Head and Neck Cancer general poster session on Monday, June 1 from 8:00AM until 12:00PM on Level 2 in West Hall C.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemorad
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 6, 2015  Shenzhen Beike Biotechnology Co., ... the world,s largest stem cell provider, has ... packets containing no less than 50 million ... reduce the time and cost of stem ... of degenerative conditions such as Ataxia, Motor ...
(Date:5/6/2015)... 6, 2015  Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a ... tumor cancers, today announced that Linda Powers , NW Bio ... cancer vaccine platform for solid tumor cancers and the Company,s ...   , , , DATE: , , ... TIME: , , , 12:15 PM EDT , , ...
(Date:5/6/2015)... Dr Jaspreet Singh , Senior Research Officer from ... the 2015 Asian Starch Conference, to be held ... , As an honored ... Starch: A Potential Source for the Creation of Next ... a 528 page text book entitled "Advances in Potato ...
(Date:5/5/2015)... Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular diagnostics ... of foodborne pathogens,  today announced that Paul G. Thomas ... 2015 Health Care Conference on May 12 at 8:00am PT. ... Las Vegas NV. ... the investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Beike Biotechnology Produces High-dose Adult Stem Cell Packets for Degenerative Conditions 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 2NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2
... Experience to Company , , ... Xceleron, the global leader in predictive clinical research to ... Ph.D., has been named President and CEO after an ... Xceleron a balance of sales, operations and management know-how, ...
... 16 Parion Sciences, Inc., a,privately-held, development-stage pharmaceutical ... of the body,s mucosal defenses, today,announced that the ... a biodefense grant in excess of $850,000. , ... of the grant is to advance the development ...
... NXTM ), a leading manufacturer of innovative dialysis ... and Robert Brown, Chief Financial Officer, will be presenting at ... the Westin St. Francis Hotel in San Francisco. , ... for Wednesday, January 14th at 4:30 p.m. PT. To ...
Cached Biology Technology:Xceleron Names Michael Butler as President & CEO 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3NxStage to Present at the JPMorgan Healthcare Conference 2
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... lymphoma kinase, which has been reported in other cancers ... primary driver of the rapid metastasis that patients with ... use of anaplastic lymphoma kinase (ALK) inhibitors may be ... form of breast cancer. These data were presented ...
... COPENHAGEN, DENMARK -- Analysis of a massive set of ... (GBIF) Data Portal has helped quantify the influence of ... a particular area. A team of Israeli scientists ... mammal occurrence records with detailed coordinates in the ,lower ...
... Infectious diseases specialists from Austin Health are working closely ... how Staph is becoming resistant to all antibiotic therapies. ... Staphylococcus aureus (Golden Staph) is complicated by ... to infections can be at additional risk if antimicrobial ...
Cached Biology News:Signaling pathway linked to inflammatory breast cancer may drive disease metastasis 2Use of GBIF helps clarify environment-species links 2Researchers closer to the super bug puzzle 2
Request Info...
... Kit is designed for rapid preparation ... over commonly used transformation procedures such ... include:- Cells can be made competent in ... preparation and transformation solutions are optimized ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: